Eventide Asset Management LLC Raises Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Eventide Asset Management LLC increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 0.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,635,406 shares of the specialty pharmaceutical company’s stock after purchasing an additional 750 shares during the period. Collegium Pharmaceutical accounts for 1.8% of Eventide Asset Management LLC’s investment portfolio, making the stock its 12th biggest position. Eventide Asset Management LLC owned about 8.17% of Collegium Pharmaceutical worth $101,832,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Pacer Advisors Inc. boosted its stake in Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after buying an additional 821,541 shares during the last quarter. Rubric Capital Management LP boosted its position in shares of Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after acquiring an additional 499,473 shares during the last quarter. Vanguard Group Inc. grew its holdings in Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after purchasing an additional 17,942 shares during the period. Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after purchasing an additional 113,300 shares during the period.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $30.71 on Friday. Collegium Pharmaceutical, Inc. has a 12-month low of $25.16 and a 12-month high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market capitalization of $990.40 million, a price-to-earnings ratio of 13.24 and a beta of 0.95. The firm’s fifty day moving average price is $35.11 and its 200 day moving average price is $34.62.

Insider Activity

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. The trade was a 13.81 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Truist Financial boosted their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Piper Sandler reissued a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright raised their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.